Scoring system to guide treatment after kidney cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study uses a scoring system to help decide if patients with stage III clear cell kidney cancer should receive extra treatment after surgery. It aims to personalize care and avoid unnecessary treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage III clear cell renal cell carcinoma (a type of kidney cancer).
- You are in good overall health, with a performance status score of 0 or 1 (meaning you can care for yourself and are mostly active).
- You have not received any anti-cancer treatment before your kidney surgery.
- You had a radical nephrectomy (complete removal of the kidney tumor) with clear margins (no cancer left behind).
- You are not pregnant or breastfeeding, and you do not have severe other illnesses like heart disease, COPD, diabetes, or chronic kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial studies how well people do—especially their quality of life—after SBRT radiation for primary kidney cancer that can’t be removed with surgery. It may help doctors understand which patients benefit most and what side effects to expect.
This study tests whether taking axitinib plus an immunotherapy drug (PD-1) before surgery can help people with kidney cancer live longer without the cancer coming back. It’s focused on people who have a higher-risk kidney tumor based on scans and pathology findings.
This trial tests a combination of two drugs, cardenilimab and lenvatinib, given before and after surgery to remove kidney cancer. The goal is to see if this approach helps prevent the cancer from coming back. It is for people with early-stage (non-spread) clear cell kidney cancer who are healthy enough for surgery.
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.